clinical trial · NCT07388511
A Study of Elenestinib in Healthy Adult Female Participants
Healthy ParticipantsElenestinibMidazolamLevonorgestrel/Ethinyl Estradiol
brief summary
The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.
started
Feb 5, 2026
primary completion
Apr 2, 2026
completion
Apr 2, 2026
last updated
Apr 20, 2026
official title
A Phase 1, Open-Label Study to Evaluate the Effect of Elenestinib on the Pharmacokinetics of Midazolam and Combined Oral Contraceptives, Levonorgestrel/Ethinyl Estradiol, in Healthy Adult Female Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol